STVN:NYSE, Stevanato Group S.p.A.

STVN stock overview

Stevanato Group S.p.A. (STVN:NYSE) closed at $19.64 on October 27, 2026, down 1.21% on the day. The stock trades 27.3% below its 52-week high of $27.00 and 52.4% above its 52-week low of $12.89. Over the past year, it lost 23.8%. Stevanato Group S.p.A. is part of the Health Care sector.

Key figures

Price: $19.64
Day change: -1.21%
Volume: 250,523
Average volume: 393,342
Market cap: 5B+
52-week range: $12.89 – $27.00
50-day average: $20.73
200-day average: $18.12

Price action over the past year

In 252 trading sessions since October 27, 2025, STVN closed higher on 117 days (46%). Its best day was March 4, 2026 (+18.81%) and its worst was January 23, 2026 (-9.86%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 2 times.

Recent signals

Oct 27, 2026: Trading sideways between $18.82 and $21.41 over 30 days (Sideways scanner)
Oct 27, 2026: News catalyst: Patnership (News Catalysts scanner)

STVN news

Oct 27, 2026: Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Oct 27, 2026: Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Oct 26, 2026: Stevanato's Margin Story Faces A Third-Quarter Test As Balda Exit Mutes Reported Growth
Oct 20, 2026: Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
Oct 1, 2026: Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables
Oct 1, 2026: United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
Sep 18, 2026: electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
Sep 8, 2026: Stevanato Group to Participate in Two Upcoming Investor Conferences

About Stevanato Group S.p.A.

Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages.

Similar stocks

Find more stocks like STVN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.